BridgeBio Pharma BBIO Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's non-cash lease expense?
- BridgeBio Pharma (BBIO) reported non-cash lease expense of $1.47M in Q1 2026.
- How has BridgeBio Pharma's non-cash lease expense changed year-over-year?
- BridgeBio Pharma's non-cash lease expense increased by 47.5% year-over-year, from $994K to $1.47M.
- What does non-cash lease expense mean?
- The non-cash portion of lease costs recognized over time.
- How do you interpret non-cash lease expense?
- Stable values indicate consistent leasing activity; significant changes suggest shifts in office or facility footprint.
- How does non-cash lease expense compare across companies?
- Standard for all companies reporting under modern lease accounting standards.